COMPAMIR
High-Purity Fact Pipeline
© 2026 COMPAMIR | Verified Intelligence
High-Purity Fact Pipeline
Eli Lilly, Boehringer Ingelheim
Alzey, Germany
June 3, 2026
Verified: June 3, 2026
"Eli Lilly is cutting its planned 2.3 billion euro investment in Alzey by half. The decision is a response to proposed German health legislation involving higher rebates and price controls. Boehringer Ingelheim also announced a 900 million euro investment cut in Germany."
Author: Peter J. Neumann
This book provides a deep dive into the complex relationship between pharmaceutical innovation, government regulation, and drug pricing, which is central to the conflict between Eli Lilly and the German government.
As an Amazon Associate, COMPAMIR earns from qualifying purchases.